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Background: The overexpression of angiopoietin-2 (Ang-2) has both pro-tumorigenic and anti-tumorigenic effects.
However, the mechanisms of this protein’s dual effects are poorly understood, and it remains unclear how Ang-2
cooperates with vascular endothelial growth factor (VEGF). In the current study, we investigated the effects of
Ang-2 overexpression on nasopharyngeal carcinoma growth in the presence of different levels of VEGF.
Methods: Ang-2 was introduced into the CNE2 cell line by liposome transfection, and the expression of
endogenous VEGF was inhibited by microRNA-mediated RNA interference. CNE2 cells expressing varying levels of
Ang-2 and VEGF were injected subcutaneously into the flanks of nude mice. Tumor growth was measured, and
vessels from the harvested tumors were analyzed.
Results: The overexpression of Ang-2 had no obvious effect on CNE2 tumor growth in the presence of endogenous
VEGF but significantly inhibited CNE2 tumor growth when the expression of endogenous VEGF was silenced, and the
Ang-2/VEGF ratio is negatively correlated with tumor growth. Ang-2 overexpression decreased the percentage of
α-SMA-positive cells around the tumor vessels but reduced the microvessel density only in the absence of VEGF.
Conclusions: Our results indicate that the effects of Ang-2 on nasopharyngeal carcinoma are highly dependent on the
level of VEGF expression, Ang-2/VEGF ratio may offer a novel therapeutic approach for treating human cancer.
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The development and growth of solid tumors depend on
the pathological formation of new blood vessels. Over the
last decade, much research has focused on elucidating the
important role of angiopoietin-2 (Ang-2) in tumor angio-
genesis. Ang-2, a member of the Ang family, acts as an
agonist in Tie2 signaling and disrupts the integrity of ma-
ture vessels. The overexpression of Ang-2 has both pro-
tumorigenic [1-6] and anti-tumorigenic effects [7-10]. The
molecular mechanisms of the dual properties of Ang-2 are
poorly understood. The effects of Ang-2 are highly context
dependent and are associated with the level of vascular
endothelial growth factor (VEGF). One possible explan-
ation is that Ang-2 destabilizes blood vessels by disrupting* Correspondence: haihong_zju@hotmail.com
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unless otherwise stated.the interactions between endothelial cells (ECs) and peri-
ECs, causing Ang-2 to accelerate vessel regression in the
absence of VEGF. However, in the presence of VEGF,
Ang-2 enhances VEGF stimulation and promotes the
sprouting of new vessels from disrupted vessels. Indeed, in
non-small cell lung cancer patients, an angiogenic effect
of Ang-2 was seen only when VEGF expression was high
[11]. According to this hypothesis, the overexpression of
Ang-2 and the inhibition of VEGF may have a comple-
mentary effect on the suppression of tumor growth. How-
ever, some studies have shown that Ang-2 limited the
antivascular effects of VEGF inhibition [12]. Research per-
formed by Hashizume [13] yielded the same result, indi-
cating that inhibiting the expression of both Ang-2 and
VEGF had additive effects on sprouting and vessel regres-
sion, resulting in the further slowing of tumor growth.
The complexities of the function of Ang-2 are highly cell
context dependent and have not been adequately explored.td. This is an Open Access article distributed under the terms of the Creative
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improved understanding of the roles of Ang-2 in tumor
angiogenesis and the cooperation of Ang-2 with VEGF will
lead to advances in the development of effective anti-
angiogenic and anti-cancer therapies.
In this study, to gain insight into the dual roles of Ang-2
and its potential connection to VEGF, towards the ultimate
goal of enhancing the efficacy of Ang-2-based therapeutic
interventions, we investigated how Ang-2 overexpression
influences tumor growth in the presence of different levels
of VEGF. Nasopharyngeal carcinoma (NPC) is one of the
most common cancers in Southern China, South Asia, and
North Africa [14,15]. It is highly invasive and metastatic.
The standard treatment for NPC is radiotherapy; however,
the survival rate remains low. Angiogenesis is closely corre-
lated with the progression of NPC and the effect of radi-
ation therapy [16,17]. Accumulating evidence suggests that
the overexpression of VEGF is positively correlated with
tumor growth, metastatic potential, the failure of radiother-
apy, and a poor prognosis [18,19]. However, limited evi-
dence suggests that Ang-2 plays a role in NPC. We
evaluated the combined effects of Ang-2 and VEGF on the
angiogenic activity of nasopharyngeal carcinoma, and con-
cluded that Ang-2 can suppress tumor growth and angio-
genesis when the VEGF level is low, and the Ang-2/VEGF
ratio is negatively correlated with tumor growth.
Materials and methods
Cell lines and culture conditions
The CNE2 human nasopharyngeal carcinoma cell line was
obtained from the cell bank of the Shanghai Institute of
Biochemistry and Cell Biology. The cells were cultured
and maintained in RPMI 1640 medium (GIBCO) supple-
mented with 10% fetal bovine serum, 100 IU/mL penicil-
lin, 100 mg/mL streptomycin, and 2 mM L-glutamine at
37°C in 5% CO2 and 95% air.
Transfection of CNE2 cells with VEGF-specific miRNAs
Pre-miRNA oligo sequences for VEGFA (Gene ID:7422)
were designed by Invitrogen’s Oligo Designer3.0 to target
the gene sequence 5’-AACCATGAACTTTCTGCTGT-3’
(bases 1034–1054). The synthesized complementary DNA
oligos targeting VEGF (forward oligo: 5’-TGCTGGACAGC
AGAAAGTTCATGGTTGTTTTGGCCACTGACTGAC
AACCATGATTTCTGCTGTC-3’, reverse oligo: 5’-CCT
GGACAGCAGAAATCATGGTTGTCAGTCAGTGGC
CAAAACAACCATGAACTTTCTGCTGTCC-3’) or tar-
geting a random sequence (forward oligo: 5’-TGCTGAA
ATGTACTGCGCGTGGAGACGTTTTGGCCACTGACT
GACGTCTCCACGCAGTACATTT-3’, reverse oligo: 5’-C
CTGAAATGTACTGCGTGGAGACGTCAGTCAGTGG
CCAAAACGTCTCCACGCGCAGTACATTTC-3’) were
annealed to generate a double-stranded oligo and cloned
into the linearized pcDNA™ 6.2-GW/EmGFP-miR vector(Invitrogen, catalog no. K4936-00) using T4 DNA ligase.
All of the vectors were transformed into DH5α Chemically
Competent E. coli (Invitrogen Corp.), and the colonies con-
taining spectinomycin-resistant transformants were ana-
lyzed for the desired expression clones. The recombinant
vectors were purified with an Endotoxin-free plasmid DNA
purification kit (NucleoBond® Xtra Midi EF) and confirmed
by sequencing. The purified vectors were transfected into
CNE2 using Lipofectamine 2000 (Invitrogen, catalog no.
11668-027) according to the manufacturer’s instructions,
and cell lines stably integrating the pre-miRNA oligo se-
quences were selected out by Blasticidin S HCl (Invitrogen,
catalog no. R210-01). Once transcribed, the pre-miRNAs
will be further processed to give rise to the following ma-
ture miRNAs: VEGF miRNA: sense strand 5’-ACAGCAG
AAAGTTCATGGTT-3’, antisense strand 5’-AACCATG
ATTTCTGCTGT-3’; scrambled miRNA: sense strand 5’-A
AATGTACTGCGCGTGGAGA-3’, antisense strand 5’-T
CTCCACGCAGTACATTT-3’. The silencing effects of
these miRNAs were verified by qRT-PCR and Western blot
analysis.
Subcloning of Ang-2 into pcDNA3.1/(-)B and the
transfection of cells
The Ang-2 gene was amplified by polymerase chain re-
action (PCR) from the pBLAST49-hANGPT-2 plasmid
(Invitrogen) and inserted into the pcDNA3.1(-)B vector
(Invitrogen, San Diego, CA) at the BamH1 and EcoRI
sites. Recombinant plasmids were identified by restric-
tion enzyme analysis and DNA sequencing. The Ang-2
expression vector pcDNA3.1(-)B/Ang-2 was transfected
into CNE2 cells, VEGF miRNA-transfected CNE2 cells,
and scrambled miRNA-transfected CNE2 cells using a
liposome transfection reagent. Parental CNE2 and CNE2
cells transfected with the empty pcDNA3.1(-)B vector were
used as negative controls. Selective medium containing
G418 (500 μg/mL) and blasticidin (2 μg/mL) was added 24
h later, and viable colonies were selected and expanded.
Ang-2 and VEGF expression were evaluated by real-time
RT-PCR and Western blot respectively. The expanded cells
were harvested for in vivo animal experiments.
Quantitative real-time RT-PCR
Total RNA was extracted from tumor cells or tissues using
the TRIzol reagent (Invitrogen) according to the manufac-
turer's instructions. The RNA was further purified using
the RNeasy Mini kit (Generay). cDNAs were synthesized
using the Revert Aid First Strand cDNA synthesis Kit (Ap-
plied Fermentas). qRT-PCR was performed in a CFX con-
nect Real-Time PCR System by using the SYBR Green
PCR master mix (Applied Bio-Rad). The PCR cycle pa-
rameters were as follows: 50.0°C for 3 min, 95°C for 3
min, 40 cycles with denaturation at 95°C for 10 sec, an-
nealing at 59.0°C for 20 sec, and extension at 72°C for 20
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and repeated in three independent experiments. The rela-
tive quantities of selected mRNAs in cell or tissue samples
were normalized to that of GAPDH. The specific primer














For the tumorigenicity assay, 5-week-old male nude mice
were obtained from the Shanghai Slac Laboratory Animal
Co. Ltd. and acclimated for 1 week. The mice were then
caged in groups of four. The mice were randomly assigned
to one of six treatment groups. The body weight at the
time of assignment did not differ among the groups. After
the viability of the cells had been verified by a trypan blue
exclusion test, 2 × 106 cells (in 0.2 mL Hank’s balanced salt
solution) of each cell line were injected subcutaneously
into the right flank of one nude mouse to expand the cell
population in vivo (the first inoculation). Rapidly prolifer-
ating tumors were resected, and the necrotic tissue was re-
moved. Viable tumor tissues of each treatment group
from each mouse were cut into 2 mm3 pieces, and then
subcutaneously inoculated into the right flanks of 9 new
nude mice (the second inoculation). For the first inocula-
tion, each mouse was injected with one of the following
types of cells: parental CNE2 cells treated with only the
liposome transfection reagent (group A: mock), empty-
pcDNA3.1(-)B-transfected CNE2 cells (group B: control
plasmid), Ang-2-transfected CNE2 cells (group C: Ang-
2 plasmid), Ang-2-transfected and scrambled miRNA-
transfected CNE2 cells (group D: Ang-2 + scrambled
miRNA), Ang-2-transfected and VEGF miRNA-transfected
CNE2 cells (group E: Ang-2 +VEGF miRNA), VEGF
miRNA-transfected CNE2 cells (group F: VEGF miRNA).
After the second inoculation, the animals were observed
daily. The growth of each tumor was measured every three
days. The tumor volume was calculated as V (cm3) = 1/2ab2
(a: length, b: width). All mice were sacrificed under sodium
pentobarbital anesthesia on the 27th day after the second
inoculation. The tumors were harvested, weighed, and used
for qRT-PCR, Western blot and immunohistochemical
analyses.Detection of Ang-2 and VEGF protein expression
The Ang-2 and VEGF protein expression levels were deter-
mined by Western blot analysis. The lysates from tumor
cells or tissue were subjected to SDS-PAGE, and the pro-
teins were transferred to a nitrocellulose membrane (Milli-
pore). The membrane was incubated with primary
antibodies against Ang-2 (GTX100927, Gene Tex) or VEGF
(9003-1-AP, Protein Tech), followed by incubation with a
horseradish peroxidase-conjugated goat anti-rabbit IgG
(BS13278, Bioworld). The membrane was incubated with
the enhanced chemiluminescence plus detection reagent
and exposed to film. The densitometric intensities of the
bands were then compared.
Histological and immunocytochemical examination
Solid tumors from mice were embedded in paraffin wax
after dehydration using an ethanol series. A rabbit poly-
clonal antibody against α-smooth muscle actin (α-SMA)
was purchased commercially (Proteintech Group Inc).
Formaldehyde-fixed, paraffin-embedded tissue sections
were deparaffinized in xylene and rehydrated in alcohol.
Then, the sections were incubated in 3% hydrogen perox-
ide to block endogenous peroxidase activity. Each slide
was incubated with normal goat serum for 30 min at room
temperature and then with the α-SMA antibody overnight
at 4°C. After incubation with a biotinylated mouse anti-
goat IgG (working dilution, 1:200) for 30 min at room
temperature, each slide was rinsed with PBS and incu-
bated with an avidin-biotin peroxidase complex for 30
min at 37°C. The peroxidase was visualized using a 3,3’-di-
aminobenzidine tetrahydrochloride solution, and the sec-
tions were counterstained with methyl green. α-SMA is a
marker of smooth muscle cells, which normally associate
with endothelial cells to form mature vascular structures.
In this study, the immunohistochemical staining of α-
SMA was used to assess the maturity of the vessels.
Tumor vascularity
Solid tumors from different groups of injected mice were
embedded in paraffin wax after dehydration. Tumor pieces
were each cut into 5 μm consecutive paraffin sections and
stained with the EC-specific marker CD34 (Proteintech
Group Inc., 1:200), followed by detection using the avidin-
biotin complex method and 3,3’-diaminobenzidine accord-
ing to the instructions. The microvessel density (MVD)
was calculated according to the method reported by
Weidner et al. [20]. Briefly, low-power light microscopy
(magnification × 100) was used to scan the often heteroge-
neous tumor sections to identify the areas with the highest
levels of neovascularization. Any individual endothelial cell
or endothelial cell cluster that was positive for CD34 and
was clearly separate from all nearby clusters was consid-
ered a countable microvessel. Individual microvessels were
counted in the three areas with the highest vascular density
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number of vessels in these areas and was recorded as the
MVD. The MVD was determined by two separate
investigators.
Statistical analysis
The values were expressed as the means ± SD. Normality
of the data was tested using SPSS, revealing all the experi-
mental data as normally distributed data. The significance
of the differences between experimental groups was deter-
mined by ANOVA in SPSS version 11.0. P values of <0.05
were considered statistically significant.
Results and discussion
Parental CNE2 cells express a relatively high level of
VEGF, which was silenced by VEGF-specific miRNA
VEGF-specific miRNA was transfected into CNE2 cells
using Lipofectamine 2000 and cells stably integrating the
pre-miRNA oligo sequences were selected for the follow-
ing experiments. We compared the expression of VEGF
between the VEGF miRNA-transfected CNE2 cells and
the control cells using qRT-PCR and Western blot ana-
lyses. The results showed the expression of VEGF was
higher in the parental CNE2 cells and scrambled miRNA-
transfected CNE2 cells but significantly lower in the VEGF
miRNA-transfected CNE2 cells (p < 0.05, Figure 1), with
a 76% reduction of endogenous VEGF, indicating that
the VEGF miRNA effectively interfered with VEGF
expression.
Successful expression of ectopic Ang-2 in CNE2 and
VEGF-interfered CNE2 cells
The purified full-length cDNA for Ang-2 was subcloned
into the pcDNA3.1(-)B vector using T4 DNA ligase. TheFigure 1 Effects of VEGF silencing on CNE2 cells. CNE2 cells were treate
(scrambled miRNA), or a VEGF-specific miRNA (VEGF miRNA). (a): Real-time
CNE2 cells. *P < 0.05, compared with the mock and scrambled miRNA grou
in the VEGF-interfered CNE2 cells.insert was verified by DNA sequencing as human Ang-2
(accession number: NM001147).
The pcDNA3.1(-)B/Ang-2 vector was then transfected
into CNE2 and VEGF-silenced CNE2 cells using lipo-
somes. Stable clones were selected. A higher level of Ang-
2 in Ang-2-transfected cells was confirmed by real-time
quantitative RT-PCR and Western blot. The levels of Ang-
2 and VEGF expression and the ratio of Ang-2/VEGF in
the six groups of cells were shown in Figure 2.Overexpression of Ang-2 had no effect on CNE2 tumor
growth but greatly suppressed growth when the VEGF
level was low.
Small tumor pieces derived from the first round of inocu-
lation with one of the six groups of CNE2 cells - mock,
control plasmid, Ang-2 plasmid, Ang-2 + scrambled
miRNA, Ang-2 + VEGF miRNA and VEGF miRNA - were
inoculated subcutaneously into the flanks of nude mice to
establish CNE2 xenografts. After the second inoculation,
tumor growth was monitored daily and compared among
the different groups. No obvious side effects were ob-
served during the experimental period. The group transge-
nically expressing Ang-2 had no obvious effect on CNE2
tumor growth compared with the mock and control plas-
mid transfected groups. However, the transgenic expres-
sion of Ang-2 greatly suppressed tumor growth in the
VEGF-silenced CNE2 cells. VEGF miRNA group also had
a prominent inhibitory effect on tumor growth, but Ang-
2 + VEGF miRNA group which had a higher Ang-2/VEGF
ratio exhibited an even higher degree of tumor suppres-
sion than the VEGF miRNA group (Figure 3a).
All mice were sacrificed on the 27th day after the second
inoculation. qRT-PCR and Western blot analysis of the
harvested tumors revealed higher Ang-2 expression in thed with the transfection reagent only (mock), a scrambled miRNA
RT-PCR demonstrated low VEGF mRNA expression in VEGF-interfered
ps. (b): Western blotting demonstrated lower VEGF protein expression
Figure 2 Expression levels of Ang-2 and VEGF in different engineered CNE2 cell groups. (a): mRNA expression was determined by
qRT-PCR. All the PCR amplification was performed in triplicate and repeated in three independent experiments. The relative quantities of selected
mRNAs in cell samples were normalized to that of GAPDH. Higher Ang-2 mRNA expression was observed in C, D, and E (**P < 0.01, vs. B, no
significant difference among A, B and F). Lower VEGF mRNA expression was observed in group E and F (## P < 0.01, # P < 0.05, vs. A, B, C, D).
(b): Western blots of the above samples. (c): Densitometric quantitation of the band intensities shown in (b). The densitometric intensity of the
target band in each lane relative to the intensity of the GAPDH band from the same sample was calculated, and plotted. Data were expressed as
means ± SD of three independent experiments. The level of total Ang-2 protein in the Ang-2-transfected group C,D,E was significantly higher than
that in control group B (*P < 0.05 vs. B; no significant difference among A, B and F), and the level of endogenous VEGF protein in the VEGF
miRNA-transfected group E,F was significantly decreased (## P < 0.01, vs. A, B, C, D). The ratio of Ang-2/VEGF was significantly higher in E and F
than in other groups.
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the VEGF-silenced CNE2 group (P < 0.05, Additional file
1: Figure S1). The weights of the transplanted tumors on
treatment day 27 from the six groups were presented in
Figure 3b. There were no significant differences betweenthe Ang-2 transgenic group and the controls (P > 0.05).
However, Ang-2 expression combined with VEGF miRNA
resulted in a greatly decreased tumor weight compared
with those of the other five groups including VEGF
miRNA group (P < 0.05, Figure 3b).
Figure 3 Effect of Ang-2 overexpression on CNE2 tumor growth under different VEGF level. Six groups of engineered CNE2 cells with
different Ang-2 and VEGF levels were subcutaneously inoculated into six groups of nude mice (A-F) respectively. Tumor volumes were calculated
dynamically (a), and tumors were weighed (b) when the mice were sacrificed on the 27th day after inoculation. There was no significant
difference on tumor development among A,B,C. (P > 0.05), while E and F exhibited greatly suppressed tumor growth compared with A,B,C,D
(**P < 0.01, *P < 0.05 vs A,B,C,D, ## P < 0.01 vs F). E had higher inhibitory effects than F on tumor growth.
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when the VEGF level was low
To determine the number of microvessels, CD34 immu-
noreactivity was detected in vascular endothelial cells.
Microvessels appeared as brown capillaries or small clus-
ters standing out from other tissue. The MVDs in tumors
derived from the different types of cells were analyzed.
There was no significant difference between the Ang-2-
transfected CNE2 tumors and the control tumors (P >
0.05). However, the tumors derived from the VEGF-
silenced CNE2 groups exhibited a significantly decreased
MVD relative to the other groups (Table 1, Figure 4).
To evaluate the effects of Ang-2 overexpression on the
maturation of tumor vessels, α-SMA was detected by
immunohistochemical staining. There were typically
fewer α-SMA-positive cells around the tumor vessels in
the Ang-2-transfected groups than in the mock and con-
trol plasmid groups. Tumor vessels in Ang-2-transfected
groups displayed aberrant structures characterized by
distorted, dilated or narrow vessel lumina (Figure 5).
This result indicated that the vessels in the Ang-2-
transfected tumors were immature.Ang-2 plays an important role in angiogenesis during
the development and growth of human cancers. This pro-
tein increases the permeability of the vascular endothelial
layer of mature blood vessels and makes the vessel more
plastic. Ang-2 modulates tumor angiogenesis in a coopera-
tive manner with other angiogenic factors, especially
VEGF. Although almost all tumors exhibit upregulated
Ang-2 expression, the roles of Ang-2 in tumor angiogen-
esis were found to be complex and variable, and its exact
effects depend on the tumor model investigated.
Past studies have shown that overexpression of Ang-2 aug-
ments tumor angiogenesis and growth and is associated with
a poor prognosis. For example, Ang-2-expressing MKN-7
gastric carcinoma cells developed tumors with hypervascu-
larity and a high metastatic potential [21]. When Tanaka
et al. [22] injected Ang-2 overexpressing human HuH7 he-
patocellular cancer cells into the livers of nude mice, all of
the mice exhibited extensive bleeding at death, after the for-
mation of large tumors. The same result was found for neu-
roendocrine tumors [4] and colon cancer [6]. These findings
support the hypothesis that overexpression of Ang-2 can
lead to increased tumor growth and hypervascularity.
Table 1 Immunohistochemical staining for CD34 was
used to determine the MVD in harvested tumors derived
from the different CNE2 groups (MVD in 200× field)
Group MVD
A: mock 22.89 ± 3.15
B: control plasmid 23.04 ± 3.61
C: Ang-2 plasmid 21.67 ± 3.51
D: Ang-2 + scrambled miRNA 21.11 ± 2.97
E: Ang-2 + VEGF miRNA 9.48 ± 2.23** ##
F: VEGF miRNA 12.04 ± 3.03**
**: P < 0.01 vs. A,B,C,D; ## P < 0.01 vs F.
no significant difference among A,B,C (P > 0.05), by ANOVA.
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cific induction of Ang-2 in gliomas, mammary carcin-
omas, and lung carcinomas inhibits tumor growth and
metastasis [7-9]. By impairing the pericyte coverage of the
tumor vasculature, Ang-2 induced massive regression of
the tumor vascular and exacerbated tumor hypoxia, effects
that significantly inhibited tumor angiogenesis, promoted
tumor apoptosis, and suppressed tumor growth [10].
Interestingly, some studies indicated that Ang-2 had no
significant effect on tumor growth. For example, Sung-Suk
Chae et al. [23] showed that ectopic expression of Ang-2
had no effect on U87 glioma tumor growth. Study from H
Yoshiji et al. [24] also indicated that overexpression of
Ang-2 did not increase hepatocellular carcinoma develop-
ment. Our current results are in line with their findings.Figure 4 Images for CD34 staining in harvested tumor tissues with m
microvessel density (MVD) in A,B,C,D group, while lower MVD in E and F (V
d: Ang-2 + scrambled miRNA, e: Ang-2 + VEGF miRNA, f: VEGF miRNA. OrigWhy does Ang-2 have different effects on different
tumor types or models? Our results revealed that the level
of Ang-2 relative to VEGF (i.e., the ratio of Ang-2/VEGF)
rather than its absolute level might be critical in tumor
suppression. It is well established that tumor angiogenesis
is regulated by a variety of proangiogenic factors, among
which, VEGF and Ang-2 are the two most important fac-
tors that seem to play coordinated roles in vascular devel-
opment to support tumor growth. The Ang-2-Tie2
interaction has been shown to increase the permeability of
the vascular endothelial layer of mature blood vessels by
disrupting interactions between endothelial cells (ECs)
and peri-ECs, inducing a localized region of vessel plasti-
city. This plasticity facilitates EC migration, exposing ECs
to proliferation signals from angiogenesis inducers, espe-
cially VEGF [25]. Initially, when there is a low level of en-
dogenous VEGF expression, Ang-2 destabilises vessels by
removing pericytes and causing irreversible loss of vascu-
lar structures and relative hypoxia, which may collectively
suppress tumor growth. However, hypoxia can drive the
release of VEGF, and in the presence of VEGF, Ang-2 may
induce an angiogenic response and promote vascular
sprouting from disrupted vessels, and eventually, high ex-
pression of Ang-2 and VEGF leads to robust angiogenesis.
Therefore, it is reasonable to speculate that the relative
level of Ang-2 versus VEGF is important in controlling the
angiogenic switch and tumor growth, and up-regulating
Ang-2 while down- regulating VEGF simultaneously may
be an effective therapeutic approach for suppressingicrovessel density measured. It showed that there were higher
EGF silenced group). a: mock, b: control plasmid, c: Ang-2 plasmid,
inal magnifications: 200× for a,b,c,d,e,f.
Figure 5 Immunohistochemical staining for α-SMA in harvested tumor tissues. The results showed that there were fewer α-SMA-positive
cells around endothelial cells in the Ang-2-transfected groups (c,d,e) than in non- Ang-2-transfected groups (a,b,f). In addition, this staining
showed vessels in c,d,e displayed an aberrant structure characterized by distorted and dilated lumina (vessel indicated by arrow). a: mock,
b: control plasmid, c: Ang-2 plasmid, d: Ang-2 + scrambled miRNA, e: Ang-2 + VEGF miRNA, f: VEGF miRNA, g: negative control. Original
magnifications: 400× for a,b,c,d,e,f,g.
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tumor at different stages, the ratio of Ang-2/VEGF may
vary, which could offer an explanation for the different ef-
fects of Ang-2 and its stage-dependent roles in tumor
growth. In our current study, when VEGF expression was
effectively silenced by miRNA, overexpression of Ang-2 ac-
celerated vessel regression and suppressed tumor growth.
There were fewer α-SMA-positive cells around the vessels
in Ang-2-transfected tumors, and vessels displayed aberrant
structures characterized by distorted ,dilated or narrow ves-
sel lumina, but there were no significant difference in
microvessel density (MVD) between Ang-2-transfected
group and the control. However, Ang-2 overexpression to-
gether with VEGF-silencing significantly decreased MVD
indicating that the immature vessels induced by Ang-2
were partially regressed in the low level of VEGF.
Conclusions
In summary, our study showed that the effects of Ang-2
overexpression on nasopharyngeal CNE2 tumor growth aredependent on the VEGF expression level. Specifically, Ang-
2 can greatly inhibit tumor growth in the low level or ab-
sence of VEGF, and the Ang-2/VEGF ratio is negatively
correlated with tumor growth. These results may have the
following important implications: firstly, It is now widely
recognized that VEGF and Angs are two central endothe-
lium specific growth families coordinating tumor angiogen-
esis, but how they operated are still unclear. Our data
indicated combination of Ang-2 and VEGF may provide a
more reliable prognostic index for some cancers. Secondly,
for the first time, our data revealed the importance of a
high ratio of Ang-2/VEGF in suppressing tumor growth,
and clearly demonstrated the advantageous effects of simul-
taneously elevating Ang-2 level and lowering VEGF level,
and potentially opened new avenues for angiogenic factor-
based anticancer therapy. However, our conclusions were
largely based on experiments employing only the CNE2 cell
line, further studies are required to determine whether the
combined targeting of Ang-2 and other angiogenic cyto-
kines in a variety of primary cancer tissues and cancer cell
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vention for the treatment of cancer.
Additional file
Additional file 1: Figure S1. Expression levels of Ang-2 and VEGF in
tumor tissues resected from mice inoculated with different engineered
CNE2 cells. (a): mRNA expression was determined by qRT-PCR. Higher
Ang-2 mRNA expression was observed in C, D, and E (*P< 0.05 vs. B, no
significant difference among A,B and F). Lower VEGF mRNA expression
was observed in group E and F (# P < 0.05, vs. A, B, C, D). (b): Western
blots of the above samples. (c): Densitometric quantitation of the band
intensities shown in (b). The level of total Ang-2 protein in the Ang-2-
transfected group C,D,E was significantly higher than that in control
group B (*P<0.05, vs. B; no significant difference among A, B and F), and
the level of endogenous VEGF protein in the VEGF miRNA-transfected
group E,F was significantly decreased (## P<0.01, vs. A, B, C, D). The ratio
of Ang-2/VEGF was significantly higher in E and F than in other groups.
Abbreviations
Ang: Angiopoietin; Ang-2: Angiopoietin-2; VEGF: Vascular endothelial growth
factor; ECs: Endothelial cells; α-SMA: α-smooth muscle actin;
NPC: nasopharyngeal carcinoma; qRT-PCR: Reverse transcription-polymerase
chain reaction; MVD: Microvessel density; GAPDH: Glyceraldehyde-3-
phosphate dehydrogenase.
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